U.S. Markets open in 9 hrs 30 mins

Taiwan Liposome Company, Ltd. (TLC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.99+0.18 (+3.10%)
At close: 4:00PM EDT

Taiwan Liposome Company, Ltd.

No. 3 Yuanqu Street
11th Floor-1 Nangang District
Taipei 11503
Taiwan
886 2 2655 7377
http://www.tlcbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Keelung HongFounder, Chairman & CEO305.44kN/A1943
Mr. Zhi-Hong Yeh M.B.A.Pres269.93kN/A1972
Ms. Ru-Yun Lin M.B.A.CFO and VP of Fin. & Admin.N/AN/A1966
Ms. Carina Chen M.B.A.Principal Financial & Accounting Officer and Director of Fin. & Admin.67.97kN/A1981
Mr. Thomas H. Bliss Jr., M.B.A.Chief Bus. Officer61.43kN/A1967
Dr. George Spencer-Green M.D., M.S.Chief Medical Officer249.75kN/A1947
Dr. Yunlong Tseng Ph.D.VP of R&D134.8kN/A1967
Dr. Vincent Chang B.Sc. (Chem), Ph.D., M.Sc.VP of Manufacturing Devel.102.12kN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19.Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.

Corporate Governance

Taiwan Liposome Company, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.